Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	81.52	124.9	215.12	689.8	119.1
Short-Term Investments	639.36	825.28	267.17	187.21	369.62
Cash & Cash Equivalents	720.88	950.19	482.29	877.02	488.72
Cash Growth	-24.13%	97.02%	-45.01%	79.45%	-2.09%
Receivables	42.83	36.94	37.03	25.31	23.41
Inventory	21.22	29.7	21.82	8.58	0
Other Current Assets	23.46	29.83	12.89	16.85	4.65
Total Current Assets	808.39	1,047	554.03	927.76	516.79
Property, Plant & Equipment	115.65	115.2	120.86	101.67	111.11
Long-Term Investments	84.32	161.27	557.53	677.87	64.41
Other Long-Term Assets	40.89	26.78	19.81	11.09	15.39
Total Long-Term Assets	240.86	303.25	698.2	790.63	190.91
Total Assets	1,049	1,350	1,252	1,718	707.69
Accounts Payable	4.71	2.73	8.33	4.37	4.79
Deferred Revenue	5.6	18.29	36.58	41.16	46.07
Current Debt	42.21	27.43	8.09	7.94	6.82
Other Current Liabilities	162.4	134.78	96.76	77.34	48.79
Total Current Liabilities	214.92	183.23	149.77	130.8	106.48
Long-Term Debt	290.29	215.02	103.32	81.67	89.13
Other Long-Term Liabilities	413.43	436.97	28.41	35.83	47.73
Total Long-Term Liabilities	703.72	651.99	131.73	117.5	136.85
Total Liabilities	918.64	835.23	281.49	248.31	243.34
Total Debt	332.5	242.45	111.41	89.6	95.95
Debt Growth	37.14%	117.62%	24.33%	-6.61%	-
Retained Earnings	-2,339.94	-1,832.96	-1,275.44	-631.36	-945.24
Comprehensive Income	-3.5	-10.44	-4.13	-5.21	-2.54
Shareholders' Equity	130.61	514.68	970.74	1,470	464.36
Net Cash / Debt	388.38	707.74	370.88	787.41	392.77
Net Cash / Debt Growth	-45.12%	90.83%	-52.90%	100.48%	-21.31%
Net Cash Per Share	6.41	11.87	6.34	14.02	8.21
Working Capital	593.47	863.42	404.26	796.96	410.3
Book Value Per Share	2.16	8.63	16.59	26.96	9.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).